Loading...
•
Mar 31, 2021
Penumbra Q1 2021 Earnings Report
Reported revenue increase of 23.2% and vascular products grew to 50.5% for the first quarter of 2021.
Key Takeaways
Penumbra, Inc. reported a revenue of $169.2 million in the first quarter of 2021, representing a 23.2% increase compared to the first quarter of 2020. The company's vascular product sales grew by 50.5%, while neuro product sales increased by 2.5%.
Total revenue increased to $169.2 million, a 23.2% increase compared to Q1 2020.
Vascular product revenue grew by 50.5% compared to Q1 2020.
Neuro product revenue grew by 2.5% compared to Q1 2020.
Operating income for the first quarter of 2021 was $13.5 million.
Penumbra
Penumbra
Penumbra Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company is increasing its guidance for 2021 total revenue to be in the range of $695 million to $705 million, which represents growth of 24% to 26% over 2020 revenue of $560.4 million.
Positive Outlook
- Increased revenue guidance for 2021.
- Projected revenue growth of 24% to 26% over 2020.
- New revenue range compares favorably to the previous range.
- Continued focus on innovative therapies.
- Strong sales organization in the United States, Europe, Canada and Australia.
Challenges Ahead
- Impact of the COVID-19 pandemic on business.
- Risk of failure to sustain or grow profitability.
- Potential delays in product introductions.
- Significant competition in the market.
- Risk of unfavorable outcomes in clinical trials.
Revenue & Expenses
Visualization of income flow from segment revenue to net income